Zoetis receives EUA for Simparica Trio
The FDA authorizes the chewable tablets to treat New World screwworm infestations in dogs and puppies during this emergency.
See the latest news and media coverage for Zoetis. We track all announcements, press releases, and industry mentions in real time, all in one place.
Global animal health company
zoetis.comLast updated
In short: Zoetis cut its 2026 financial outlook after missing quarterly estimates due to softening demand in the U.S. companion animal market.
The FDA authorizes the chewable tablets to treat New World screwworm infestations in dogs and puppies during this emergency.
Net income was $691 million. The company cites pressured companion animal markets and adjusts full-year organic growth expectations.
Saccaro joins effective August 17, 2026, from GE HealthCare. He leads global finance and operations, while Wetteny Joseph transitions to a special advisor role.
The long-acting anti-NGF monoclonal antibody provides pain relief for up to three months with a single injection
Impax Asset Management, based in London and specializing in sustainable investing, released its Q2 2026 investor letter for the “Impax US Sustainable Eco...
Disappointing quarterly results impacting overall performance.Reduced consumer spending affecting...
Zoetis Inc. (NYSE:ZTS) entered 2026 as a leader in animal health, but its latest earnings show that even a strong market position cannot fully insulate...
The FDA authorized Zoetis’s Simparica TRIO—already sold since 2020 for heartworm, fleas and ticks—fo...
Track Zoetis and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.
Browse news for competitors to Zoetis and other trending companies.